12:00 AM
 | 
Jul 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PRO 542: Phase I/II

PGNX published in The Journal of Infectious Diseases previously reported data from a 15-patient Phase I study that showed dose-dependent reductions in plasma...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >